MedTrace Logo

EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress

NCT07027657 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-03-30

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether the treatment with BTL-699-2 device is able to improve sleep quality and reduce stress in adults above the age of 22 years. The main questions it aims to answer are:

Does the treatment with BTL-699-2 device improve sleep quality? Does the treatment with BTL-699-2 device reduce stress?

Participants will be asked to:

* Undergo six treatments
* Complete the Pittsburgh Sleep Quality Index
* Complete the Perceived Stress Scale Questionnaire
* Complete the Sleep and Stress Assessment Questionnaire
* Complete the Therapy Comfort and Subject Satisfaction Questionnaire

Conditions

  • Sleep Quality
  • Stress Reduction

Interventions

DEVICE

Treatment with BTL-699-2

Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.

DEVICE

Treatment with BTL-699-2 (sham)

Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 5% of the individual's motor threshold.

Sponsors & Collaborators

  • BTL Industries Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-02
Primary Completion
2025-11-11
Completion
2025-11-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07027657 on ClinicalTrials.gov